Why do children experience milder symptoms on average compared to adults? Do children experience Long Covid, and what makes them different? What is MIS-C and what is its prevalence? I explore recent research to answer these questions.
Category: pharma & healthcare
The N Protein, A New Target For Anti-Covid Drugs
FDA-approved drug inhibits SARS-CoV-2 nucleocapsid phosphorylation and viral replication.
Do You Have The “Thin” Gene?
Happy Thanksgiving! As you dig into your Thanksgiving dinner, a time when many of us overeat, you may well ask: Will I regret it tomorrow when I check my weight? Will it be ok?
CRISPR Technology To Simplify And Enhance CAR T Cancer Treatment
Researchers find that combining novel gene-editing CRISPR technology with CAR T therapy could simplify and improve CAR T therapy in one fell swoop.
Hope For A New Treatment On The Horizon For Zika Virus
An uncommon monoclonal antibody treatment for Zika Virus may be on the horizon in the wake of new research on the pathogen.
Inflation Reduction Act Drug Pricing Provisions Aren’t At All Like Price Controls In Europe
The Inflation Reduction Act’s drug pricing provisions aren’t at all like price controls in Europe. They’re not nearly as comprehensive or draconian. And, they’re not universal, that is, they don’t apply to the commercial market.
FDA’s Push To Reclassify The Opioid Reversal Agent Naloxone As An OTC Product Needs To Show More Urgency
The FDA’s push to reclassify naloxone as an OTC product appears tepid and plodding. At a time when the nation is enduring a severe public health emergency – with record numbers of (illicit) opioid overdose-related deaths – it’s crucial that naloxone be…
Researchers Control Cancer Treatment With New Innovation: CAR T Switch(blade)
The early study result from Scripps Research suggests that switchable CAR T cells are not only safe to use for patients with B cell cancers, but comparatively safer and more effective than some CAR T therapies currently on the market.
Gantenerumab’s Phase 3 Flop Means Lecanemab Emerges As Favorite In Antibody Class Targeting Amyloid Plaque In Alzheimer’s Patients
Gantenerumab’s flop in Phase 3 means that lecanemab emerges as the preliminary favorite in the antibody class of biologics targeting beta-amyloid plaque in Alzheimer’s Disease patients. But, several key market access challenges lie ahead for the Alzhei…
New Monoclonal Antibody For Treatment Of Malaria
A new monoclonal antibody treatment for malaria may soon aid the millions impacted by the disease annually.
